medigraphic.com

2010, Number 3

<< Back Next >>

Rev Hosp Jua Mex 2010; 77 (3)

Efectos de la D-norpseudoefedrina sola y combinada con liotironina sobre la reactividad vascular en un vaso de conductancia y en el lecho vascular coronario de la rata

Castillo-Henkel C, Guzmán-Lozano NL, López-Canales JS, Guevara-Balcázar G, Asbun-Bojalil J, Rodriguez-Choreño D, Morín-Zaragoza R, Villanueva-López GC, Mendoza-Zepeda R

Language: Spanish
References: 17
Page: 163-169
PDF size: 53.99 Kb.


ABSTRACT

Introduction. The D-norpseudoephedrine is an adrenergic amine with indirect action may be combined with liothyronine, aspect to consider in the risk-benefit analysis of drugs used in the treatment of obesity. Material and methods. The effect of Dnorpseudoephedrine on the aorta of male rats of the Wistar strain, under the protocol of the Bioethics Committee of the School of Medicine, Instituto Politecnico Nacional. The statistics were analyzed with ANOVA test. Results. The D-norpseudoephedrine induced a concentration-dependent contraction to well below the peak effect of phenylephrine. When the tone has been previously raised with phenylephrine, the D-norpseudoephedrine induces a concentration-dependent relaxation with a maximum effect of 25.07 ± 1.99% of reversion of the contractile effect induced by phenylephrine. Thyroid hormone did not alter the maximum effect of the D-norpseudoephedrine (0.1950 ± 0.01 vs. 0.1818 ± 0.01, in the absence and presence of liothyronine, respectively). Adrenergic amine caused a concentration-dependent increase in perfusion pressure with a lower maximum effect caused by phenylephrine (Emax 95.4 ± 12 and 39.2 ± 22.14 mmHg in the case of phenylephrine and D-norpseudoephedrine, respectively). Conclusions. The D-norpseudoephedrine causes contraction of the aorta at high concentrations (generally above those achieved in the clinic). When is pre vascular tone increased, the D-norpseudoephedrine independently reduces the contractile agent used or the presence of vascular endothelium. Moreover, the D-norpseudoephedrine increases coronary perfusion pressure, but to a lesser degree than phenylephrine. Prior administration of T3 offset the increase in coronary perfusion pressure caused by the D-norpseudoephedrine.


REFERENCES

  1. Norma Oficial Mexicana. NOM-174-SSA1-1998. Para el manejo integral de la obesidad. Publicado en el Diario Oficial de la Federación 12-abril-2000.

  2. González-Barranco J. Obesidad: problema de salud pública en México. Nutrición Clínica 2002; 5: 213-8.

  3. Goertz AW, Hübner C, Seefelder C, Seeling W, Lindner KH, Rockemann MG, et al. The effect of ephedrine bolus administration on left ventricular loading and systolic performance during high thoracic epidural anesthesia combined with general anesthesia. Anesth Analg 1994; 78: 101-5.

  4. Kobayashi S, Endou M, Sakuraya F, Matsuda N , Zhang X-H, Azuma M, et al. The sympathomimetic actions of L-Ephedrine and D-Pseudoephedrine: direct receptor activation or norepinephrine release. Anesth Analg 2003; 97: 1239-45.

  5. Kikta DC, Fregly MJ. Effect of In Vitro administration of captopril on vascular reactivity of rat aorta. Hypertension 1982; 4: 118-24.

  6. Frosch F. Biopharmaceutical investigations with Dnorpseuephedrine. Arzneimittelforschung 1977; 27(3): 665-8.

  7. Lake CR, Gallant S, Masson E, Miller P. Adverse drug effects attributed to phenylpropanolamine: a review of 142 case reports. Am J Med 1990; 89: 195-208.

  8. Pentel P. Toxicity of over-the-counter stimulants. JAMA 1984; 252: 1898-903.

  9. Morgan JP, Funderburk FR. Phenylpropanolamine and blood pressure: a review of prospective studies. Am J Clin Nutr 1992; 55 (Suppl.): 206S-10S.

  10. Radack K, Deck CC. Are oral decongestants safe in hypertension? An evaluation of the evidence and a framework for assessing clinical trials. Ann Allergy 1986; 56: 396-401.

  11. Dhar R, Stout CW, Link M, Homoud MK, Weinstock J, Mark NA. Estes NAM III: Cardiovascular toxicities of performance-enhancing substances in sports. Mayo Clin Proc 2005; 80(10): 1307-15.

  12. Nyska A, Murphy E, Foley JF, Collins BJ, Petranka J(†), Howden R, et al. Acute hemorrhagic myocardial necrosis and sudden death of rats exposed to a combination of ephedrine and caffeine. Toxicological Sciences 2005; 83: 388-96.

  13. Dunnick JK, Kissling G, Gerken DK, Vallant MA, Nyska A. Cardiotoxicity of Ma Huang/caffeine or ephedrine/caffeine in a rodent model system. Toxicologic Pathology 2007; 35: 657-64.

  14. Shekelle PG, Hardy ML, Morton SC, Maglione M, Mojica WA, Suttorp MJ, et al. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a metaanalysis. JAMA 2003; 289: 1537-45.

  15. Salerno SM, Jackson JL, Elizabeth P. Berbano EP. Effect of oral pseudoephedrine on blood pressure and heart rate: A Metaanalysis. Arch Intern Med 2005; 165: 1686-94.

  16. Córdova-Villalobos JA, Barriguete-Meléndez JA, Lara-Esqueda A, Barquera S, Rosas-Peralta M, Hernández-Ávila M y cols. Las enfermedades crónicas no transmisibles en México: sinopsis epidemiológica y prevención integral. Salud Pública de México 2008; 50(5): 419-27.

  17. Wooltorton E, Sibbald B. Ephedra/ephedrine: cardiovascular and CNS effects. Can Med Assoc J 2002; 166: 633.




2020     |     www.medigraphic.com